ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing

Hodgkin lymphoma (HL) resistant to conventional therapies is increasing, making of interest the search for new schemes of treatment. Members of the “A Disintegrin And Metalloproteases” (ADAMs) family, mainly ADAM10 or ADAM17, have been proposed as therapeutic targets in solid tumors and some ADAMs i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Main Authors: Zocchi, Maria Raffaella, Camodeca, Caterina, Nuti, Elisa, Rossello, Armando, Venè, Roberta, Tosetti, Francesca, Dapino, Irene, Costa, Delfina, Musso, Alessandra, Poggi, Alessandro
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2015
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910733/
https://ncbi.nlm.nih.gov/pubmed/27467923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1123367
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares